Company profile
Mangoceuticals, Inc.
NASDAQ: MGRX · Healthcare · Medical - Healthcare Information Services
#939 of 1,418 Healthcare companies by revenue26th-percentile growth
EA Score
30DFH 35DQ 19GM 42SS 21
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, 3-yr revenue growth · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$315.2k
Rev growth YoY (TTM)
-38.9%
Net income (FY)
-$20.6M
Employees
3
as of 2026-08-23
Market cap
$7.2M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$456.0k$456.0k2025
Net income-$20.6M-$20.6M2025
Operating income-$18.0M-$18.0M2025
Total assets$16.1M$16.1M2025
Liabilities$890.6k$890.6k2025
Equity$15.2M$15.2M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Mangoceuticals, Inc.’s revenue?
Mangoceuticals, Inc. booked $456.0k in FY2025 revenue, contracting 26% year over year — slower than 74% of Healthcare companies we track, at a -4526.8% net margin.
Peers · Healthcare
Pasithea Therapeutics Corp.32DPositron Corporation28DSpeedus Corp.——Integrative Health Technologies, Inc.——Alternate Health Corp.——EnviroTechnologies International, Inc——Neighbors
Dallas →Key facts
CEOJacob D. Cohen
SectorHealthcare
IndustryMedical - Healthcare Information Services
HeadquartersDallas, TX
ExchangeNASDAQ: MGRX
Employees3
IPO date2023-03-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.